Development

Systematic, data-driven science coverage · Wednesday, July 29, 2026
The AllSci BriefSystematic R&D and deal news. Daily.
Most Read
Business

Caldera taps reverse merger to advance TL1A × IL-23 bispecific

Caldera taps reverse merger to advance TL1A × IL-23 bispecific
Business

Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy

Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy
Business

AbCellera adds Vertex as latest TCE platform partner in autoimmune disease

AbCellera adds Vertex as latest TCE platform partner in autoimmune disease
Business

Qnovia bets on antimicrobial peptides with exclusive UVA deal

Qnovia bets on antimicrobial peptides with exclusive UVA deal
Business

LB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications

LB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications
More from Development
Shape Therapeutics secures funding to advance one-time gene therapy for Parkinson's disease.
Development

Shape Therapeutics secures funding to advance one-time gene therapy for Parkinson's disease.

Seattle-based Shape Therapeutics has received a research grant from The Michael J. Fox Foundation for Parkinson's Research to fund IND-enabling studies of...

6h agoFDA clears registrational Phase II path for Cullinan's CLN-049 in relapsed/refractory AML
Development

FDA clears registrational Phase II path for Cullinan's CLN-049 in relapsed/refractory AML

Cullinan Therapeutics (Nasdaq: CGEM) announced on July 28 that the FDA endorsed its Phase II development strategy for CLN-049, a FLT3×CD3 bispecific T cell...

10h agoAtea's hepatitis C combination meets non-inferiority bar, clears path to regulatory filing
Development

Atea's hepatitis C combination meets non-inferiority bar, clears path to regulatory filing

Boston-based Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline results from its Phase III C-BEYOND trial on July 28, with the fixed-dose...

10h agoAltimmune's pemvidutide sees clear path forward in alcohol use disorder after strong Phase II
Development

Altimmune's pemvidutide sees clear path forward in alcohol use disorder after strong Phase II

Gaithersburg, Maryland-based Altimmune, Inc. (Nasdaq: ALT) reported positive topline results from the RECLAIM study, a Phase II trial of pemvidutide in...

1d agoTreeline opens Phase I trial of TLN-499 plus venetoclax in BCL-2-dependent solid tumors
Development

Treeline opens Phase I trial of TLN-499 plus venetoclax in BCL-2-dependent solid tumors

Treeline Biosciences, Inc. has registered a first-in-human Phase I clinical trial of TLN-499 in combination with venetoclax (Venclexta) in patients with...

1d agoProMIS reports no ARIA-E in blinded six-month Alzheimer's trial update
Development

ProMIS reports no ARIA-E in blinded six-month Alzheimer's trial update

ProMIS Neurosciences (Nasdaq: PMN) reported blinded six-month interim safety and biomarker data from its Phase Ib Alzheimer's disease trial on Monday, with...

1d agoViiV's two-drug Dovato matches three-drug Biktarvy in first head-to-head HIV trial
Development

ViiV's two-drug Dovato matches three-drug Biktarvy in first head-to-head HIV trial

ViiV Healthcare reported Week 48 data from the phase IIIb VOGUE study showing that dolutegravir/lamivudine (Dovato) met a non-inferiority endpoint against...

1d agoAstraZeneca's sonesitatug vedotin delivers first Phase III OS win for CLDN18.2 ADC in gastric cancer
Development

AstraZeneca's sonesitatug vedotin delivers first Phase III OS win for CLDN18.2 ADC in gastric cancer

AstraZeneca's sonesitatug vedotin (CMG901, AZD0901) has demonstrated a statistically significant and clinically meaningful overall survival benefit in...

1d ago
The AllSci BriefSystematic R&D and deal news. Daily.
MapLight's M1/M4 agonist aces Phase II schizophrenia trial
Development

MapLight's M1/M4 agonist aces Phase II schizophrenia trial

MapLight Therapeutics (Nasdaq: MPLT) reported positive topline results from its Phase II ZEPHYR trial of ML-007C-MA in adults with acute exacerbation of...

2d agoGossamer reacquires seralutinib rights ahead of September NDA submission in PAH
Development

Gossamer reacquires seralutinib rights ahead of September NDA submission in PAH

Gossamer Bio (Nasdaq: GOSS) announced on July 27 that FDA meeting minutes from a mid-June Pre-NDA Type B meeting support a September 2026 NDA submission for...

2d agoInnoCare's oral TYK2 meets primary endpoint in Phase III psoriasis trial
Development

InnoCare's oral TYK2 meets primary endpoint in Phase III psoriasis trial

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced that fadeucravacitinib, its oral TYK2 inhibitor, met the primary endpoint with statistical significance...

2d agoRevagenix opens first clinical trial of LpxC inhibitor for Pseudomonas-driven bronchiectasis
Development

Revagenix opens first clinical trial of LpxC inhibitor for Pseudomonas-driven bronchiectasis

San Francisco-based Revagenix, Inc. has dosed the first participant in a Phase I trial of Rev-56, an inhaled therapy targeting chronic Pseudomonas...

2d agoCAMP4 launches first-in-human trial of antisense therapy for SYNGAP1 disorder in Australia
Development

CAMP4 launches first-in-human trial of antisense therapy for SYNGAP1 disorder in Australia

Cambridge, Massachusetts-based CAMP4 Therapeutics Corporation (Nasdaq: CAMP) has received clearance from Australia's Therapeutic Goods Administration (TGA)...

2d agoBio-Thera advances CD25-targeted ADC into first human trial for solid tumors.
Development

Bio-Thera advances CD25-targeted ADC into first human trial for solid tumors.

Bio-Thera Solutions, Ltd. (SH: 688177), a Guangzhou, China-based commercial-stage pharmaceutical company, has dosed the first patient in a Phase I trial of...

2d agoUltomiris misses Phase III endpoint in adult HSCT-TMA, leaving pediatric approval path intact
Development

Ultomiris misses Phase III endpoint in adult HSCT-TMA, leaving pediatric approval path intact

AstraZeneca (LSE/STO/NYSE: AZN) reported that ravulizumab (Ultomiris) failed to meet the primary endpoint in a Phase III placebo-controlled trial in adults...

2d ago